Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The tolerability of and adherence to intermittent short-term rifabutin-isoniazid preventive treatment was assessed in subjects dually infected with Mycobacterium tuberculosis and the human immunodeficiency virus (HIV). In a randomised, open-label, phase II pilot study, 44 subjects received either rifabutin 300 mg and isoniazid 750 mg twice weekly for 3 months (group A, n = 16) or the same regimen with rifabutin at 600 mg (group B, n = 14), or isoniazid 300 mg/day for 6 months (group C, n = 14). Three, two and four subjects in groups A, B, and C, respectively, did not complete their treatment (one case of flu-like syndrome in group B; one methadone withdrawal syndrome in group A; and patient decision in two cases in group A and four in group C). Overall, adverse events were reported by four, nine, and seven subjects in groups A, B and C, respectively. Intermittent combined rifabutin + isoniazid for 3 months had lower default rates than daily standard isoniazid for 6 months. The regimen with rifabutin at 300 mg dose compared favourably to standard isoniazid, and warrants larger efficacy studies to assess its role for the prevention of latent tuberculosis in HIV-infected subjects.

Type

Journal article

Journal

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Publication Date

11/1999

Volume

3

Pages

1043 - 1046

Addresses

Clinic of Infectious and Tropical Diseases, University of Brescia, Italy. forleo@master.cci.unibs.it

Keywords

Humans, Tuberculosis, AIDS-Related Opportunistic Infections, Isoniazid, Rifabutin, Antibiotics, Antitubercular, Antitubercular Agents, Drug Therapy, Combination, Drug Administration Schedule, Pilot Projects, Drug Tolerance, Adult